ESMO - Eur. Oncology· @myESMO · X·· 18 小时前评分70
正文 · 机器翻译
今天终于是 #ESMO26 的大日子！
@ProfGLongMIA 将公布 INTerpath-001 的完整结果，随后由 Inge Marie Svane 对数据进行专业解读，并结合具体背景展开分析。
千万别错过主席专题论坛 I
⏰16:30 - 18:15
📍阿利坎特礼堂 - 6号厅
60 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA1按 Presidential Symposium I 对上
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.orgAhead of #ESMO26, #CancerVaccines are generating global attention, but what questions still need answering before they can reshape #ClinicalPractice? Read more in an interview with James Larkin, ESMO Congress 2026 Scientific Co-Chair 🔗 https://ow.ly/Hzug50ZXEg9 #InsightsbyESMO在 X 查看被引用的帖子
来源：ESMO - Eur. Oncology · x.com